Miami, Florida (PRWEB) September 18, 2011
While R-Alpha Lipoic is produced by the human body and, found in many foods, thus a nutrient, but the study has made a specific reference to R-Alpha Lipoic as "Disease-modifying agent", which normally is granted for medicinal purposes.
The study is correct in one hand and incorrect in the other.
R-Alpha Lipoic is used as a co-therapy for Diabetic Polyneuropathy for more than 40 years in Germany and in Japan had a medicinal designation until 2004. Even in US, the FDA granted a special license an associate of National Institutes of Health, Dr. Berkson, for medicinal application of R-Alpha Lipoic.
However, there is a definite and clear distinction between R-Alpha Lipoic "the nutrient" and R-Alpha Lipoic "the therapeutic agent”. The difference is the method of administration.
In Germany and even in US, when FDA granted a special license to Dr. Berkson, the application is intravenously, and the result of such applications have been astounding, not only in diabetes but also other disease. But the administration of intravenous R-Alpha Lipoic can only be done by a trained physician.
R-Alpha Lipoic from conventional food or supplements is only nutrient and while it theoretically possesses the same ability of the R-Alpha Lipoic "the medicine", but since there are no clinical studies on any adverse effects of high supplemental dosage of R-Alpha Lipoic, then it should only be considered as a dietary nutrient, a potent dietary anti-oxidant.
As to “Therapeutic R-Alpha Lipoic”, according to the published studies in Biochem. & Biophy. Res. Comm., R-Alpha Lipoic reduced the accumulation of Triglycerides in the fat tissue, the underlying cause of insulin resistance in Obesity, as well as activating a protein called AMPK, the very same target of many anti-diabetic agents ( American Heart Association, Inc). (1,2)
Moreover, other studies published in The Journal of Biological Chemistry, R-Alpha Lipoic inhibited the formation of the fat cells (pre-adipocytes diffrentiation of 3T3-L1 cell line), an important finding for the role of R-Alpha Lipoic in Obesity. (3)
However, any therapeutic application of R-Alpha Lipoic must be intravenously and administered by a licensed and trained physician.
As to the nutrient R-Alpha Lipoic, it is without a doubt that its dietary supplementation offers nutritional benefits. But caution must be given for high supplemental intake of R-Alpha Lipoic, since there are no clinical studies, shedding light to the intake, tolerance or adverse effect and, more importantly, the supplemental intake of R-Alpha Lipoic (since it is a nutrient) cannot guaranty a constant / specific delivery to the blood.
The human body produces R-Alpha Lipoic but its production decreases by age. R-Alpha Lipoic is a nutrient and found in variety of foods, such as spinach and broccoli, but its levels do not increase, significantly, through conventional food and thus its dietary supplementation is the preferred choice for those looking to have its ideal benefits.
In conclusion, Nutri-Med Logic Corp agrees with the study published in “Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy”, but adds that the study failed to mention that there is distinction between the supplemental intake and intravenous administration.
Nutri-Med Logic Corp is a producer of dietary supplements, including R-Alpha Lipoic, with a different recommended daily intake for men and women.
Nutri-Med Logic's products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and packaged in pharmaceutical facilities.
It must be noted that the studies, sources or statements, above and below, have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of R-Alpha Lipoic dietary supplementation; nor equate its supplementation to prevention, treatment or cure.
(1) Biochemical and Biophysical Research Communications, Vol 332, Issue 3, 8 July 2005, pp 885-891
(2) Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2488.
(3) The Journal of Biological Chemistry, 12 Sept. 2003 278, 34823-34833